Fundamental company data provided by Zacks Investment Research. Compare Top Brokerages Here. Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T). All rights reserved. Identify stocks that meet your criteria using seven unique stock screeners. The … Akebia Therapeutics stock forecast, AKBA price prediction: Buy or sell Akebia Therapeutics, Inc. shares? AKBA Stock Forecast - Get a free AKBA stock predictions and find out whether you should buy or sell AKBA stock. For the fiscal quarter endingMar 2021, the consensus EPS* forecast has decreased over the past week from -0.28 to -0.3 (7.14%) and decreased over the past month from -0.28 to -0.3 (7.14%). Earnings for Akebia Therapeutics are expected to grow in the coming year, from ($1.77) to ($0.72) per share. In 2023, AKBA is forecast to generate $41,557,244,647 in revenue, with the lowest revenue forecast at $33,860,982,158 and the highest revenue forecast at $53,303,053,329. Should I buy or sell AKBA? In the past three months, Akebia Therapeutics insiders have not sold or bought any company stock. Should I buy or sell AKBA? Want to see which stocks are moving? Akebia Therapeutics has received 392 “outperform” votes. Akebia Therapeutics Inc. Stock Price Forecast, "AKBA" Predictons for2021 Akebia Therapeutics has a market capitalization of $554.14 million and generates $335 million in revenue each year. According to the market data, Akebia Therapeutics Inc. (AKBA) stock price is $3.405 and the 52 weeks low is $2.09, which means the Akebia Therapeutics Inc. stock price is down -62.42% in the last 12 months. You may vote once every thirty days. Akebia Therapeutics, Inc. (AKBA) estimates and forecasts . Cancel. Investors can use this forecasting interface to forecast Akebia Therapeutics historical stock prices and determine the direction of Akebia Therapeutics's future trends based on various well-known forecasting models. Akebia Therapeutics Inc stock is down -1.63% over the last 12 months, and the average rating from Wall Street analysts is a Buy.InvestorsObserver’s proprietary ranking system, gives AKBA stock a score of 78 out of a possible 100.. That rank is chiefly influenced by a short-term technical score of 97. Akebia Therapeutics, Inc. (NASDAQ:AKBA) issued its quarterly earnings data on Wednesday, February, 24th. View which stocks have been most impacted by COVID-19. Andrew Francis - July 7, 2020. What is AKBA's forecast return on assets (ROA) for 2021-2024? Analyst recommendations provided by FactSet shows that the consensus forecast for Akebia Therapeutics Inc. (AKBA) is a “Overweight”. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Find real-time AKBA - Akebia Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. And are mandated by law to make a profit. AKBA Stock Forecast: All the More Reason to Consider Akebia Therapeutics Inc. (AKBA) Now. Akebia Therapeutics' stock is owned by a variety of institutional and retail investors. It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. Not a single company in this entire industry has ever gone out of business—ever. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. AKBA's revenues are forecast to grow slower (1.64% per year) than the US market average (14.8%) The biopharmaceutical company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.40) by $0.20. Another comparable company Takeda Pharmaceutical CO Ltd … On average, they expect Akebia Therapeutics' share price to reach $10.29 in the next year. Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. AKBA | Complete Akebia Therapeutics Inc. stock news by MarketWatch. Akebia Therapeutics has received 53.99% “outperform” votes from our community. Log In. Shareholders of record on Friday, June 14th will be paid a dividend of $0.3675 per share on Monday, July 1st. This represents a $1.47 annualized dividend and a yield of 2.02%. High Growth Earnings: AKBA's is expected to become profitable in the next 3 years. AKBA 3.61 0.11 … View real-time stock prices and stock quotes for a full financial overview. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Akebia Therapeutics has generated ($1.63) earnings per … View institutional ownership trends for Akebia Therapeutics. MarketBeat just released five new trading ideas, but Akebia Therapeutics wasn't one of them. View Albemarle's Dividend History. Vote “Underperform” if you believe AKBA will underperform the S&P 500 over the long term. Forecast for Fri 05 Mar 2021 price 3.43 AKEBIA THERAPEUTICS INC stock price forecast for further price development down to -7.46% (time horizon: 1 day) and price target of 3.99 USD. Earnings vs Market: AKBA is forecast to become profitable over the next 3 years, which is considered above average market growth. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The AKBA stock will be analyzed using Smart Scan and the Trade Triangle technology. View analysts' price targets for Akebia Therapeutics or view top-rated stocks among Wall Street analysts. Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. AKBA Stock Analysis Overview What this means: InvestorsObserver gives Akebia Therapeutics (AKBA) an overall rank of 44, which is below average. Find out now with a free analysis on Akebia Therapeutics. Real-time trade and investing ideas on Akebia Therapeutics AKBA from the largest community of traders and investors. 0 analysts have rated the stock as a Sell or Underperform. Get the latest Akebia Therapeutics, Inc. AKBA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Akebia Therapeutics (AKBA) stock price prediction is 3.128646 USD. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. John Butler has an approval rating of 97% among Akebia Therapeutics' employees. (Add your “outperform” vote. The biopharmaceutical company earns $-279,660,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. Analyst projections state that AKBA is forecast to be at a low of $3 and a high of $10. Get the latest Akebia Therapeutics (AKBA) stock price quote with real-time news, financials, charts and other important investing information. AKBA stock news . What is AKBA's forecast return on equity (ROE) for 2021-2024? Wall Street analysts have given Akebia Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Akebia Therapeutics 3.61 0.11 (2.96%) Watch. Short-term (time horizon: 2 weeks) AKEBIA THERAPEUTICS INC share price prediction for 2021-03-05 with daily … AKBA Stock Predictions AKBA Stock Predictions. During that period the price should oscillate between -7.35% and +13.91%. What is AKBA's revenue growth forecast for 2021-2023? Is Akebia Therapeutics Stock a good buy in 2021, according to Wall Street analysts? View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. And one last thing: the dividend yields are massive. View analyst ratings for Akebia Therapeutics or view top-rated stocks. View all of AKBA's competitors. AKBA's Return on Equity is forecast to be low in 3 years (15.18%); analysts are not confident in the firm's ability to efficiently generate return on equity, AKBA is forecast to generate lower Return on Assets (5.83%) than the US Biotechnology industry average (22.14%), AKBA's revenue is forecast to grow at a rate of -0.71% per year, which is not exceptional, AKBA's revenues are forecast to grow slower (-0.71% per year) than the US Biotechnology industry average (65%), AKBA's revenues are forecast to grow slower (-0.71% per year) than the US market average (25.24%), On average, Wall Street analysts predict that. Receive a free world-class investing education from MarketBeat. The ex-dividend date of this dividend is Thursday, June 13th. View which stocks are hot on social media with MarketBeat's trending stocks report. On average, they anticipate Akebia Therapeutics' share price to reach $9.63 in the next year. By. The U.S. House of Representatives voted to let the IMF circulate what could be a new elite-controlled reserve currency. Our latest prediction for Akebia Therapeutics Inc.'s stock price was made on the Nov. 20, 2019 when the stock price was at 3.34$. How can you protect your money and all you’ve worked for from this reset? Shares of AKBA can be purchased through any online brokerage account. Free Signup : Top 50 Stocks Top 10 Penny Stocks Bullish Engulfing Scanner … According to analyst projections, AKBA’s forecast low is $3 with $10 as the target high. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Akebia Therapeutics Stock Forecast, AKBA stock price prediction. The price has fallen in 6 of the last 10 days and is down by -18.98% for this period. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Since then, AKBA stock has decreased by 48.0% and is now trading at $3.61. The trend analysis tool will help you make a better prediction on the AKBA stock. 100% FREE. To hit the forecast high, the stock’s price needs a +194.99% upsurge from its latest level, while the stock would need to tank -11.5% for it to hit the projected low. Albemarle trades on the New York Stock Exchange (NYSE) under the ticker symbol \"ALB.\" Albemarle declared a quarterly dividend on Wednesday, May 8th. Akebia Therapeutics' management team includes the following people: I like to buy just one kind of stock and none other. Akebia Therapeutics had a negative trailing twelve-month return on equity of 68.51% and a negative net margin of 126.86%. AKBA Stock Forecast - Get a free AKBA stock predictions and find out whether you should buy or sell AKBA stock. Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. Given the current short-term trend, the stock is expected to rise 39.01% during the next 3 months and, with a 90% probability hold a price between $4.68 and $7.61 at the end of this 3-month period. Akebia Therapeutics has a P/B Ratio of 1.09. (Add your “underperform” vote.). Learn about financial terms, types of investments, trading strategies and more. Get short term trading ideas from the MarketBeat Idea Engine. The company's average rating score is 2.50, and is based on 5 buy ratings, 2 hold ratings, and 1 sell rating. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. View insider buying and selling activity for Akebia Therapeutics or or view top insider-buying stocks. Akebia Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Company insiders that own Akebia Therapeutics stock include Dell Faulkingham, Jason Amello, John P Butler, Maxine Gowen, Michel Dahan, Nicole R Hadas, Steven C Gilman and Steven Keith Burke. BOSTON (AI Forecast Terminal) Sat, Jan 30, '21 AI Forecast today took the forecast actions: In the context of stock price realization of AKBA Akebia Therapeutics is a decision making process between multiple investors each of which controls a subset of design variables and seeks to minimize its cost function subject to future forecast … As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Akebia Therapeutics, Inc. (AKBA) projections and forecasts . In 2023, AKBA is forecast to generate $-37,103,134 in earnings, with the lowest earnings forecast at $-85,277,947 and the highest earnings forecast at $13,008,500. Do Not Sell My Information. Akebia Therapeutics has received a consensus rating of Buy. Analysts tracking AKBA have forecast the quarterly EPS to grow by -$0.36 per share this quarter, while the same analysts predict the annual EPS to hit -$1.26 for the year 2021 and up to -$0.69 for 2022. 7 equities research analysts have issued 12-month price objectives for Akebia Therapeutics' stock. The official website for Akebia Therapeutics is www.akebia.com. View our full suite of financial calendars and market data tables, all for free. The consensus among Wall Street equities research analysts is that investors should "buy" Akebia Therapeutics stock. In the short term (2weeks), AKBA's stock price should outperform the market by 5.90%. Some companies that are related to Akebia Therapeutics include Myovant Sciences (MYOV), Dicerna Pharmaceuticals (DRNA), Zentalis Pharmaceuticals (ZNTL), NGM Biopharmaceuticals (NGM), Endo International (ENDP), Revance Therapeutics (RVNC), Kura Oncology (KURA), Seres Therapeutics (MCRB), Generation Bio (GBIO), Organogenesis (ORGO), Madrigal Pharmaceuticals (MDGL), Stoke Therapeutics (STOK), Ironwood Pharmaceuticals (IRWD), PMV Pharmaceuticals (PMVP) and Olema Pharmaceuticals (OLMA). Learn more. This suggests a possible upside of 202.5% from the stock's current price. What is AKBA's earnings growth forecast for 2021-2023? Akebia Therapeutics Stock Forecast is based on your current time horizon. AKBA Stock Forecast. Some bargain investors may see this as a … The P/E ratio of Akebia Therapeutics is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Akebia Therapeutics last released its earnings data on February 24th, 2021. AKBA’s announcement was unexpected and the sudden plunge of its stock price reflects that. AKBA Stock Predictions. You can opt out at any time. Learn more. Learn everything you need to know about successful options trading with this three-part video course. Top institutional investors include BlackRock Inc. (7.89%), Satter Management CO. L.P. (3.22%), Northern Trust Corp (1.21%), Dimensional Fund Advisors LP (1.21%), Dimensional Fund Advisors LP (1.14%) and Rice Hall James & Associates LLC (1.07%).
Balotario Unc 2020, Lacrosse Tribune Obituaries, Sports Monster Louisville, Crude Oil Inventory Report Today, Wagg Dog Food Rubbish, Majesty Radio Playlist, Síndrome Coronario Agudo Tratamiento, The 100 Season 7 Episode 3 Cast, Radiation Hazard Symbol, 2x4 Auto-darkening Lens Shade 10, Knoxville Fire Department Shift Schedule,
Deja una respuesta